|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics显示文摘交往受体的蛋白质 kinase-3 (RIP3 或 RIPK3 ) 是执行 “ 的细胞的机械的必要部分; programmed”或 “ regulated”坏死。这里,我们证明那规划坏死响应许多化学疗法的代理人被激活并且贡献导致化疗的房间死亡。然而,我们证明那 RIP3 表情经常在化学疗法的死亡期间由于它的 transcriptional 开始地点, MLKL 的这样 RIP3 依赖的激活和下游地规划的坏死附近的 genomic methylation 是在癌症房间的 silenced 大部分被镇压。不过,有 hypomethylating 代理人的治疗恢复 RIP3 表示,并且从而以一种 RIP3 依赖的方式把敏感提升到 chemotherapeutics。RIP3 表示在 85% 乳癌病人与正常织物相比在肿瘤被减少,建议那 RIP3 缺乏断然在肿瘤生长 / 发展期间被选择。因为 hypomethylating 代理人在病人是相当容忍得好的,我们建议病人们可以从收到 hypomethylating 代理人与常规 chemotherapeutics 在治疗以前导致 RIP3 表示有益于的那 RIP3 缺乏的癌症。 | Gi-Bang Koo Michael J Morgan Da-Gyum Lee Woo-Jung Kim Jung-Ho Yoon Ja Seung Koo Seung I1 Kim Soo Jung Kim Mi Kwon Son Soon Still Hong Jean M Mulcahy Levy Daniel A Pollyea Craig T Jordan Pearlly Yan David Frankhouser Deedra Nicolet Kati Maharry Guido Marcucci Kyeong Sook Choi Hyeseong Cho ndrew Thorbum You-Sun Kim | 2015 | Cell Research2015，25，6： | 20 |
| 2 | High expression levels of the ETS-related gene,ERG,predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:a Cancer and Leukemia Group B Study显示文摘 | Marcucci G Maharry K Whitman SP | 2007 | J Clin Oncol2007，25，22： | 1 |
| 3 | IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study显示文摘 | Marcucci G Maharry K Wu Y Z | 2010 | J Clin Oncol2010，28，14： | 1 |
| 4 | Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia:miR-155 upregulation independently identifies high-risk patients显示文摘 | Marcucci G Maharry KS Metzeler KH | 2013 | J Clin Oncol2013，31，17： | 1 |
| 5 | MicroRNA expression in cytogenetically normal acute myeloid leukemia 显示文摘 | Marcucci G Radmacher MD Maharry K | 2008 | New England Journal of Medicine2008，358，18： | 1 |
| 6 | High expression levels of the ETS-related gene,ERG,predict adverse outcome and improve molecular risk-based classi cation of cytogenetically normal acute myeloid leukemia:a cancer and leukemia group B study显示文摘 | Marcucci G Maharry K Whitman SP | 2007 | J Clin Oncol2007，25，22： | 1 |
| 7 | Prognostic significance of and gene and microRNA expression signatures associated with,CEBPA mutations in cytogenetically normal acute myeloid leukaemia with high-risk molecular features:a Cancer and Leukaemia Group B Study显示文摘 | Marcucci G Maharry K Radmacher MD | 2008 | J Clin Oncol2008，26，31： | 1 |
| 8 | MicroRNA expression in cytogenetically normal acute myeloid leukaemia 显示文摘 | Marcucci G Radmacher M D Maharry K | 2008 | N EnglJMed2008，358，18： | 1 |
| 9 | Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal aoute myeloid leukemia: a Cancer and Leukemia Group B Study显示文摘 | Schwind S Maharry K Radmacher M D | 2010 | J Clin Oncol2010，28，36： | 1 |
| 10 | RUNXl mutations are associated with poor outcome in younger and older patients with cytoge- netically normal acute myeloid leukemia and with dis- tinct gene and microRNA expression signatures显示文摘 | MENDLER J H MAHARRY K RADMACHER M D | 2012 | J Clin Oncol2012，30，： | 1 |
| 11 | Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high - risk molecular features:a cancer and leukemia Group B study 显示文摘 | Marcucci G Maharry K Radmacher MD | 2008 | Journal of Clinical Oncology2008，26，31： | 1 |
| 12 | MicroRNA expres-sion in cytogenetically normal acute myeloid leukemia 显示文摘 | MarcucciG Radmacher MD Maharry K | 2008 | N EnglJ Med2008，358，18： | 1 |
| 13 | MicroRNA expression in cytogenetically normal acute myeloid leukemia 显示文摘 | Marcucci G Radmacher MD Maharry K | 2008 | New England Journal of Medicine2008，358，18： | 1 |
| 14 | High expression levels of the ETS-related gene,ERG,predict adverse outcome and improve molecular risk-based classification of cytogeneti- cally normal acute myeloid leukemia: a Cancer and Leukemia Group B Study显示文摘 | Marcucci G Maharry K Whitman SP | 2007 | J Clin Oncol2007，25，22： | 1 |
| 15 | Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high - dose cytarabine:A Cancer and Leukemia Group B Study 显示文摘 | Neubaner A Maharry K Mrozek K | 2008 | J Clin Oncol2008，26，28： | 1 |
| 16 | TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study显示文摘 | Metzeler KH Maharry K Radmacher MD | 2011 | J Clin Oncol2011，29，10： | 1 |
| 17 | BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study 显示文摘 | Schwind S Marcucci G Maharry K | 2010 | Blood2010，116，25： | 1 |
| 18 | Prognostic significance of,and gene and microRNA expression signatures associated with,CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features:a Cancer and Leukemia Group B Study显示文摘 | Marcucci G Maharry K Radmacher MD | 2008 | J Clin Oncol2008，26，31： | 1 |
| 19 | ASXL1 nmutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category显示文摘 | Metzeler KH Becker H Maharry K | 2011 | Blood2011，118，： | 1 |
| 20 | TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study显示文摘 | Metzeler KH Maharry K Radmacher MD | 2011 | J Clini Oncol2011，29，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员